Combination chemotherapy with immune checkpoint inhibitor

This page covers all Combination chemotherapy with immune checkpoint inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting DNA (platinum agents, gemcitabine); PD-L1 (cindilimab).

Targets

DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)

Marketed (1)

• Cisplatin / Carboplatin，Gemcitabine，Cindilimab · People's Hospital of Quzhou · Oncology
  This is a combination regimen of platinum-based chemotherapy agents (cisplatin/carboplatin) and a nucleoside analog (gemcitabine), plus an anti-PD-L1 monoclonal antibody (cindilimab) that together kill cancer cells through DNA damage and immune checkpoint inhibition.

Patent intelligence

• combination chemotherapy with immune checkpoint inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates